Withdrawals due to adverse events · adult patients with refractory Crohn's disease
Methotrexate may leads to higher withdrawal due to adverse event (Feagan 1995) compared with placebo (low certainty).
3 findings from 1 review
RR 8 [1.09, 58.51]
1 study · 141 participants
Low
RR 3 [0.13, 70.42]
1 study · 52 participants
Low
RR 8.31 [0.46, 149.21]
1 study · 33 participants
Low
Failure to enter remission or possible remission at 16 weeks (Arora 1999) · adult patients with refractory Crohn's disease
Methotrexate showed no clear difference in failure to enter remission or possible remission at 24‐36 weeks… compared with 6‐MP or azathioprine (low certainty).
3 findings from 1 review
RR 1.36 [0.97, 1.92]
1 study · 58 participants
Low
RR 3.2 [0.37, 27.49]
1 study · 31 participants
Very low
RR 1.2 [0.63, 2.29]
1 study · 54 participants
Very low
Dysphagia improvement · patients with dysphagia in oesophageal cancer
1 finding from 1 review
Technical success · patients with dysphagia in oesophageal cancer
Laser showed no clear difference in technical success of procedure compared with plastic tube (moderate certainty).
1 finding from 1 review
All adverse effects · patients with dysphagia in oesophageal cancer
Laser showed no clear difference in all adverse effects compared with plastic tube (moderate certainty).
1 finding from 1 review
Recurrent dysphagia · patients with dysphagia in oesophageal cancer
Laser probably leads to lower recurrent dysphagia compared with laser plus brachytherapy (moderate certainty).
1 finding from 1 review
Adverse effects ‐ All adverse effects · patients with dysphagia in oesophageal cancer
Laser showed no clear difference in adverse effects ‐ All adverse effects compared with laser plus brachytherapy (moderate certainty).
1 finding from 1 review
Dysphagia improvement (2‐point grade or more) · patients with dysphagia in oesophageal cancer
Laser showed no clear difference in dysphagia improvement (2‐point grade or more) compared with photodynamic therapy (PDT) (moderate certainty).
1 finding from 1 review
Adverse effects ‐ All adverse effects · patients with dysphagia in oesophageal cancer
Laser showed no clear difference in adverse effects ‐ All adverse effects compared with photodynamic therapy (PDT) (moderate certainty).
1 finding from 1 review
Dysphagia improvement · patients with dysphagia in oesophageal cancer
1 finding from 1 review
Persistent or recurrent dysphagia · patients with dysphagia in oesophageal cancer
Covered Ultraflex SEMS showed no clear difference in persistent or recurrent dysphagia compared with covered Wallstent (moderate certainty).
1 finding from 1 review
All adverse effects · patients with dysphagia in oesophageal cancer
Covered Ultraflex SEMS showed no clear difference in all adverse effects compared with covered Wallstent (moderate certainty).
1 finding from 1 review
Persistent or recurrent dysphagia · patients with dysphagia in oesophageal cancer
SEMS showed no clear difference in persistent or recurrent dysphagia (analysis by concealment of… compared with plastic tube (degree of concealment) (high certainty).
3 findings from 1 review
OR 0.49 [0.19, 1.28]
4 studies · 323 participants
High
OR 0.29 [0.07, 1.21]
3 studies · 110 participants
High
OR 0.41 [0.2, 0.85]
7 studies · 433 participants
High
Subgroup analysis dysphagia improvement · patients with dysphagia in oesophageal cancer
1 finding from 1 review
All major side effects (analysis by concealment of allocation) ‐ Concealment of allocation A · patients with dysphagia in oesophageal cancer
SEMS probably leads to lower all major side effects (analysis by concealment of allocation) ‐… compared with plastic tube (degree of concealment) (moderate certainty).
1 finding from 1 review
All major side effects (analysis by concealment of allocation) ‐ Concealment of allocation non‐A · patients with dysphagia in oesophageal cancer
SEMS probably leads to lower all major side effects (analysis by concealment of allocation) ‐… compared with plastic tube (degree of concealment) (moderate certainty).
1 finding from 1 review
Dysphagia improvement · patients with dysphagia in oesophageal cancer
1 finding from 1 review
All adverse effects · patients with dysphagia in oesophageal cancer
Anti‐reflux showed no clear difference in all adverse effects compared with standard open stent (moderate certainty).
1 finding from 1 review
Adverse effects · patients with dysphagia in oesophageal cancer
Brachytherapy showed no clear difference in adverse effects compared with brachytherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Adverse effects ‐ stricture · patients with dysphagia in oesophageal cancer
Brachytherapy showed no clear difference in adverse effects ‐ stricture compared with brachytherapy plus radiotherapy (high certainty).
1 finding from 1 review